REPL Live signals | Maximize Profits with Getagraph.com

BUY 100149 min ago

@ $6.89

Issued: 14 Feb 2024 @ 14:38

Return: -6.82%

Previous signal: Feb 14 - 13:38

Previous signal: Sell

Return: -2.96 %

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:00):

Stats
Today's Volume	1.14M
Average Volume	1.30M
Market Cap	394.11M
EPS	$0 ( 2024-02-08 )
Next earnings date	( $-0.860 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.03
ATR14	$0.0190 (0.30%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Peeples-dyer Veleka	Buy	32 000	Stock Option (right to buy)
2024-04-01	Patel Sushil	Buy	250 000	Employee Stock Option (right to buy)
2024-04-01	Patel Sushil	Buy	83 335	Common Stock
2024-04-01	Pucci Paolo	Buy	32 000	Stock Option (right to buy)
2024-04-01	Xynos Konstantinos	Buy	26 665	Common Stock

INSIDER POWER
74.44
Last 98 transactions
Buy: 2 588 053 \| Sell: 457 936

Volume Correlation

Long: 0.12 (neutral)

Short: -0.38 (neutral)

Signal:(34.173) Neutral

Replimune Group Inc Correlation

10 Most Positive Correlations
BNIXU	0.927
CASS	0.908
ATIF	0.895
COLL	0.894
COFS	0.893
CNXC	0.893
NIU	0.888
FCBP	0.887
DRTT	0.884
BTAI	0.882

10 Most Negative Correlations
MTEK	-0.873
NGMS	-0.849
CRSA	-0.842
PPBT	-0.839
PLMR	-0.83
SLDP	-0.828
OSMT	-0.828
MVBF	-0.821
TCRX	-0.821
PMD	-0.819

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Replimune Group Inc Correlation - Currency/Commodity

0.11
( neutral )

0.48
( neutral )

0.00
( neutral )

-0.42
( neutral )

0.77
( moderate )

0.85
( strong )

Replimune Group Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-2.45M (0.00 %)
EPS:	$-2.99

Q3	2024
Revenue:	$0
Gross Profit:	$-700 000 (0.00 %)
EPS:	$-0.770

Q2	2024
Revenue:	$0
Gross Profit:	$-700 000 (0.00 %)
EPS:	$-0.900

Q1	2024
Revenue:	$0
Gross Profit:	$-621 000 (0.00 %)
EPS:	$-0.750

Financial Reports:

No articles found.

Replimune Group Inc

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.